Recent Advances in Protein-Drug Conjugates: From Bioanalytical, Drug Metabolism to Pharmacokinetics
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (15 March 2024) | Viewed by 4484
Special Issue Editor
Interests: drug metabolism; metabolite identification; pharmacokinetics; antibody–drug conjugates; albumin–drug conjugates; small molecules; ASO; SiRNA; PROTAC; CAR-T
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Protein–drug conjugates such as antibody–drug conjugates (ADC) have recently received significant attention due to their dramatic clinical efficacies with acceptable toxicity profiles, particularly as novel anticancer drugs. This approach comprises a protein (i.e., monoclonal antibody) conjugated to the cytotoxic payload via a chemical linker directed toward a target antigen expressed on the cancer cell surface, reducing systemic exposure and, therefore, toxicity. Thus, ADC is one of the most popular platforms but also requires a good balance among various components such as monoclonal antibody, linker, and payload from drug metabolism and pharmacokinetic perspectives. Albumin–drug conjugates (ALDCs) are another good novel platform of choice due to favorable distribution to the tumor as well as a long half-life. ALDCs are also receiving increased attention from the pharmaceutical industry as an alternative approach to overcome various cancers. In addition to protein or linker sides, new payloads are also recently introduced, such as immuno-modulators, molecular glues, and PROTACs for conjugation. Therefore, this Special Issue aims to encompass (but is not limited to) the following areas, particularly from bioanalytical, drug metabolism and pharmacokinetics, and pharmacodynamics perspectives:
- Antibody–drug conjugates (ADC);
- Albumin–drug conjugates(ALDC);
- Protein–drug conjugates (PDC);
- Novel linkers or payloads for ADC or ALDC or PDC;
- Novel payloads for ADC or ALDC or PDC.
Prof. Dr. Young G. Shin
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- protein–drug conjugates
- antibody–drug conjugates
- albumin–drug conjugates
- linkers
- payloads
- bioanalytical
- drug metabolism
- pharmacokinetics
- pharmacodynamics
